Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameluz versus placebo PDT for actinic keratosis on extremities, trunk, or neck
2017-000486-72Phase 3Completed
- Sponsor
- Biofrontera
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Ameluz + photodynamic therapy with Placebo + photodynamic therapy (2 arms). Primary endpoint: Total lesion clearance rate per patient's side. Started Jun 2017; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2017-000486-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000486-72.